Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease - Wikidata - awgldk - TriplyDB

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

http://www.wikidata.org/entity/Q35176635

about

The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis Comparative genomics and molecular dynamics of DNA repeats in eukaryotes Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease A novel GTPase, CRAG, mediates promyelocytic leukemia protein-associated nuclear body formation and degradation of expanded polyglutamine protein Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy Mouse models of polyglutamine diseases: review and data table. Part I Granzyme M mediates a novel form of perforin-dependent cell death Apoptosis: a review of programmed cell death Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice Omi / HtrA2 is relevant to the selective vulnerability of striatal neurons in Huntington's disease Effects of aging and sensory loss on glial cells in mouse visual and auditory cortices.Impaired brain creatine kinase activity in Huntington's disease.Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease.A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain Alterations in the mouse and human proteome caused by Huntington's disease.Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease.Cell death mechanisms and modulation in traumatic brain injury.Huntington disease models and human neuropathology: similarities and differences The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1 Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans.Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.The latent stem cell population is retained in the hippocampus of transgenic Huntington's disease mice but not wild-type mice.Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells.Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images.BimEL as a possible molecular link between proteasome dysfunction and cell death induced by mutant huntingtin Identification of new modulators and protein alterations in non-apoptotic programmed cell death.Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix.Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1α Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models Animal models of Huntington's disease.Cell death mechanisms in neurodegeneration.Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior.Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease.The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders.

P2860

Q24616907-37D7A9B9-931F-4D3E-8BA3-E6B81F908872 Q24650948-36B376AE-E2A9-4743-A06D-98C04A81F3EA Q24657764-FE3E61AA-0594-4D32-AD98-C3BA27AD0D6F Q24683907-D861672A-9F9B-4201-973E-A4BCDC2EC02E Q24795623-20E905DF-547D-43A1-9D3A-86D7E2963CB7 Q26849677-6822AC1D-51DE-46EB-88E6-1F1FFDAF6C80 Q26853025-9677643B-7DDE-4BC0-8FBD-8B157232B4E5 Q28251140-2D3F31D9-FDBD-4C3D-A2E0-328A5C12A018 Q28305845-04FC538E-1B3F-4DEB-BC8F-3199F786C3D0 Q28306818-49F8DCFF-B8B5-4E1C-9D09-7E45CB2EECF4 Q28510296-AC87688D-E61F-49E7-B244-19A13CB24B44 Q28568790-4A954835-AECD-44DB-878E-B61D9FF1A579 Q30455832-650384B4-F353-40DE-8478-2DFD06295462 Q30468147-867A9797-2F3F-44F1-A5BE-E7D8C52353F7 Q30480065-BE5A3BC0-CFAA-4015-B2C6-5FA167118AE2 Q30490632-73AC4543-4118-4D97-BE40-844641D9D345 Q30498862-1366D6B4-03D0-4489-87B9-A56F3C830C46 Q31096639-6A6716CF-D043-4A9D-B552-9CE36720B4AB Q33326475-59207C2D-4C59-40FD-B2EB-A955A7444216 Q33740409-CF640FDD-6ED9-4296-8869-7E1FEB6E43E4 Q33760994-611CB176-51D4-4EAA-B7EE-CAAF4FCBF104 Q33784471-F6C3A93F-0DB3-42EC-BD19-EA55515BECF2 Q33801655-06F569E4-322A-40C7-B13E-1ECFEE817E17 Q33812932-9B4EABA6-F6ED-4600-9F68-94E400E1C877 Q33859458-6A968544-01AA-42C4-8917-C75C81D3B786 Q33949349-EFC73439-209F-4505-9C3D-ED038B63809A Q34017780-613A7DE0-1351-4FC2-B8B8-82FE832BE3C6 Q34090021-A4A8144B-6D89-43F2-BEEE-4A8395325211 Q34097076-E8F7C397-4900-432F-95E0-0F5416EBA4F4 Q34137207-01C9B173-5580-47F0-8A19-96272727346A Q34163091-DDC6EF3A-DC12-45FC-B518-D2D4300CE180 Q34326791-2C35A536-31E8-4602-AC8B-52519F6E559F Q34373713-0C31AEF0-71F0-4806-AD03-C8633EBA77FE Q34391101-4A123CC7-C4DC-4CDB-9444-22D56E63BEAF Q34408158-E1E1B8ED-D678-4B18-AC47-78ACD1EDAA89 Q34665829-307DA355-6E47-4900-B394-C546C60770D6 Q34687641-E9B7DE86-CA1D-4C8C-BCC8-61E1F3013C4F Q34711201-6C53408B-AB55-4550-A043-4DD80D9FF333 Q34756441-105B4828-35BE-4C5E-9FC5-85AEF59310CA Q34769218-E0FCB82C-391B-4154-9C83-D06740A3D590

P2860

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

http://www.wikidata.org/entity/Q35176635

description

2000 nî lūn-bûn

@nan

2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

@ast

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

@en

type

label

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

@ast

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

@en

prefLabel

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

@ast

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

@en

P1433

Q35176635-50DF1446-8CFF-4019-A6CF-B9DA28D3F8AC

P1476

Q35176635-51154B94-7A9D-42CE-B68B-F2181E3F9F7B

P2093

Q35176635-4674CFD4-5B3F-4DD3-88DD-D50B60CD15E7

Q35176635-6BA0E8FB-8FCE-405F-99F1-5DC5AB25A5A7

Q35176635-71DA6404-2288-4C62-8A7B-41918166EF34

Q35176635-966C1D42-749F-46C4-98E8-C50B319D5332

Q35176635-E6B3E003-4887-4C70-AB8F-44F6EC8F4F63

P2860

Q35176635-09E8119B-2FB6-485E-9B65-234D9B3E25F0

Q35176635-17A873DF-723C-4C50-B37D-98C29E796FE4

Q35176635-27538DB6-BD7B-488A-B024-CD9901036654

Q35176635-2AB5D198-1FB4-4659-A48A-7401517C2482

Q35176635-305EC952-7F41-4570-8771-95474A3BA044

Q35176635-38411852-5439-40EF-B146-2FF660FCFAE2

Q35176635-55632766-CAE9-4A84-9FB2-3BF81F29F638

Q35176635-55801E46-0A4E-4044-9015-49A00A6F8CA9

Q35176635-5FE6A4AE-4274-4DB0-A4C0-D23D0F4058B7

Q35176635-62C12F60-3A55-4478-BED2-3FABB61ADD51

P304

Q35176635-A1E23620-8E66-4F1D-9E7F-BE9383D767F6

P31

Q35176635-48EC73BC-466A-48D4-B422-9BFC2BCA5C6D

P356

Q35176635-274E1CEE-050D-4CDB-AE05-8EFDEF6FF0E6

P407

Q35176635-1F3EB662-479D-4437-A82D-206C624FBDC7

P433

Q35176635-73A5BFD3-6F55-429A-A1DA-DB4761947840

P478

Q35176635-0681FFC6-F2A5-4FCA-AEAA-C83CC73F16B0

P50

Q35176635-44D63BA4-B30B-4373-ABD1-6135D50D0300

P577

Q35176635-7F28DDA4-A22B-4C7E-892E-7192379350F3

P5875

Q35176635-47BBD984-2B54-4B28-9887-9A4507CE90A8

P698

Q35176635-494B5342-D71F-437A-AC5E-2172BB252129

P921

Q35176635-F8FD72D7-594C-40FB-92BA-210BCD46478D

P932

Q35176635-EF33FEB7-A296-492A-A92E-E536D87D0961

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

@en

P2093

A Mahal

http://www.w3.org/2001/XMLSchema#string

A Raza

http://www.w3.org/2001/XMLSchema#string

L Mangiarini

http://www.w3.org/2001/XMLSchema#string

M Turmaine

http://www.w3.org/2001/XMLSchema#string

S W Davies

http://www.w3.org/2001/XMLSchema#string

P2860

Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures

Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

Hereditary dentatorubral-pallidoluysian atrophy: detection of widespread ubiquitinated neuronal and glial intranuclear inclusions in the brain

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

Glutamine repeats and neurodegenerative diseases: molecular aspects.

Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology.

Developmental cell death: morphological diversity and multiple mechanisms.

An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients.

P304

8093-8097

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.110078997

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

P577

2000-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12450265

http://www.w3.org/2001/XMLSchema#string

P698

10869421

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

16675

http://www.w3.org/2001/XMLSchema#string